$NVLX Nuvilex, Inc. NVLX Company Overview
NVLX Overall Average: 40% Buy
Stock Message Board http://investorshangout.com/search?q=NVLX&...mp;yt1=Go!
Last Updated: Friday, December 13, 2013 11:28:22 PM
Nuvilex, Inc. NVLX Current Price and Quotes
Last Price 0.1242
Previous Close 0.1255 Open 0.127
Daily Range 0.127 - 0.1241 52wk Range 0.22 - 0.019
Volume 902,808 Dividend N/A
Average Vol (3m) 1,563,596 Yield N/A
Nuvilex, Inc. NVLX
Company Information
12510 Prosperity Drive
Suite 310
Silver Spring, MD
Website: http://www.nuvilex.com
Phone: 240-696-6859
Email: info@nuvilex.com
Nuvilex, Inc. NVLX
Nuvilex, Inc. NVLX
Financial Reportings and Disclosures
Reporting Status U.S. Reporting: SEC Filer
Audited Financials Audited
Latest Report Jul 31, 2013 10-Q
CIK 0001157075
Fiscal Year End 4/30
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2833 - Medicinal and botanicals
Incorporated In: NV, USA
Year of Inc. 2001
Employees Not Available
Company Officers/Contacts
Robert F. Ryan President, CEO
Gerald W. Crabtree COO
Patricia Gruden CFO
Amanda Johnson Consultant
Company Directors
Not Available
Company Notes
Formerly=eFoodSafety.com, Inc. until 3-2009
Service Providers
Auditor/Accountant
Robison, Hill & Co., APC
1366 E Murray-Holladay Rd
Salt Lake City, UT, 84117
United States
M&K CPAS, PLLC
4100 North Sam Houston Pkwy W
Houston, TX, 77086
United States
Legal Counsel
Not Available
Investor Relations Firm
Not Available
Nuvilex, Inc. NVLX
NVLX Security Details
Share Structure
Market Value1 $79,145,375 a/o Dec 13, 2013
Shares Outstanding 637,241,348 a/o Sep 13, 2013
Float Not Available
Authorized Shares Not Available
Par Value 0.0001
Shareholders
Shareholders of Record 2,496 a/o Jul 29, 2013
Security Notes
Capital Change=shs increased by 3 for 1 split. Ex-date=12/08/2003. Rec date=12/02/2003. Pay date=12/05/2003.
Short Selling Data
Short Interest 13,726 (16.41%)
Nov 29, 2013
Significant Failures to Deliver No
Transfer Agent(s)
Signature Stock Transfer, Inc.
Nuvilex, Inc. NVLX Financials
Period Ending Apr 30, 2013 Apr 30, 2012 Apr 30, 2011 Apr 30, 2010
Total Revenue 12 67 126 263
Cost of Revenue 10 19 32 229
Gross Profit 3 47 94 34
Operating Expenses
Research and Development - - - 492
Sales, General and Admin. 1,402 1,669 384 1,651
Non-Recurring Items 285 327 98 3,508
Other - - - -
Operating Income (1,684) (1,949) (388) (5,617)
Income From Continuing Operations
Add'l Income/Expense Items 241 291 (838) (83)
Earnings Before Interest and Tax (1,721) (2,029) (1,226) (5,699)
Interest Expense 154 241 172 293
Earnings Before Tax (1,875) (2,270) (1,398) (5,992)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (1,598) (1,899) (1,398) (5,992)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (1,598) (1,899) (1,398) (5,992)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (1,598) (1,899) (1,398) (5,992)
Nuvilex, Inc. NVLX Recent News
Dec 12, 2013 Nuvilex's Preparations for Planned Late-Phase Clinical Trials Timely in Light of Increasing Incidence of Pancreatic Cancer
Dec 12, 2013 Nuvilex's (NVLX) Acquisition of Cellulose-based Live-Cell Encapsulation Technology Positions Company as a Leader in Development of Next Generation Cancer and Diabetes Treatments
Dec 11, 2013 Nuvilex's Contractor, Inno Biologics, Employs Clone-Pix(TM) Technology in Cloning Cells for Future Clinical Trials
Dec 9, 2013 Nuvilex Holds High Level Strategic Meetings to Solidify Company Objectives and Plans for Future Research and Development
Dec 6, 2013 Nuvilex's Subsidiary, Medical Marijuana Sciences, Inc., Appoints Dr. Mark L. Rabe as Chairman of Its Scientific Advisory Board
Dec 5, 2013 After Pancreatic Cancer, Eli Lilly and Nuvilex Could Battle Over Diabetes Treatment
Dec 4, 2013 Record Diabetes Cases Highlight Need for Nuvilex Treatment
Nov 29, 2013 Nuvilex Ahead of the Curve on Cannabidiol as FDA Issues Landmark Approval
Nov 25, 2013 Nuvilex Accelerates Development of Treatments for Cancer and Diabetes With New Corporate Management Structure
Nov 19, 2013 Nuvilex's Acquisition of Diabetes Rights Should Put the Company on Everyone's Radar
1
2
3
4
next >
NVLX Overall Average: 40% Buy
Stock Message Board http://investorshangout.com/search?q=NVLX&...mp;yt1=Go!
Last Updated: Friday, December 13, 2013 11:28:22 PM
Nuvilex, Inc. NVLX Current Price and Quotes
Last Price 0.1242
Previous Close 0.1255 Open 0.127
Daily Range 0.127 - 0.1241 52wk Range 0.22 - 0.019
Volume 902,808 Dividend N/A
Average Vol (3m) 1,563,596 Yield N/A
Nuvilex, Inc. NVLX
Company Information
12510 Prosperity Drive
Suite 310
Silver Spring, MD
Website: http://www.nuvilex.com
Phone: 240-696-6859
Email: info@nuvilex.com
Nuvilex, Inc. NVLX
Nuvilex, Inc. NVLX
Financial Reportings and Disclosures
Reporting Status U.S. Reporting: SEC Filer
Audited Financials Audited
Latest Report Jul 31, 2013 10-Q
CIK 0001157075
Fiscal Year End 4/30
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2833 - Medicinal and botanicals
Incorporated In: NV, USA
Year of Inc. 2001
Employees Not Available
Company Officers/Contacts
Robert F. Ryan President, CEO
Gerald W. Crabtree COO
Patricia Gruden CFO
Amanda Johnson Consultant
Company Directors
Not Available
Company Notes
Formerly=eFoodSafety.com, Inc. until 3-2009
Service Providers
Auditor/Accountant
Robison, Hill & Co., APC
1366 E Murray-Holladay Rd
Salt Lake City, UT, 84117
United States
M&K CPAS, PLLC
4100 North Sam Houston Pkwy W
Houston, TX, 77086
United States
Legal Counsel
Not Available
Investor Relations Firm
Not Available
Nuvilex, Inc. NVLX
NVLX Security Details
Share Structure
Market Value1 $79,145,375 a/o Dec 13, 2013
Shares Outstanding 637,241,348 a/o Sep 13, 2013
Float Not Available
Authorized Shares Not Available
Par Value 0.0001
Shareholders
Shareholders of Record 2,496 a/o Jul 29, 2013
Security Notes
Capital Change=shs increased by 3 for 1 split. Ex-date=12/08/2003. Rec date=12/02/2003. Pay date=12/05/2003.
Short Selling Data
Short Interest 13,726 (16.41%)
Nov 29, 2013
Significant Failures to Deliver No
Transfer Agent(s)
Signature Stock Transfer, Inc.
Nuvilex, Inc. NVLX Financials
Period Ending Apr 30, 2013 Apr 30, 2012 Apr 30, 2011 Apr 30, 2010
Total Revenue 12 67 126 263
Cost of Revenue 10 19 32 229
Gross Profit 3 47 94 34
Operating Expenses
Research and Development - - - 492
Sales, General and Admin. 1,402 1,669 384 1,651
Non-Recurring Items 285 327 98 3,508
Other - - - -
Operating Income (1,684) (1,949) (388) (5,617)
Income From Continuing Operations
Add'l Income/Expense Items 241 291 (838) (83)
Earnings Before Interest and Tax (1,721) (2,029) (1,226) (5,699)
Interest Expense 154 241 172 293
Earnings Before Tax (1,875) (2,270) (1,398) (5,992)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (1,598) (1,899) (1,398) (5,992)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (1,598) (1,899) (1,398) (5,992)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (1,598) (1,899) (1,398) (5,992)
Nuvilex, Inc. NVLX Recent News
Dec 12, 2013 Nuvilex's Preparations for Planned Late-Phase Clinical Trials Timely in Light of Increasing Incidence of Pancreatic Cancer
Dec 12, 2013 Nuvilex's (NVLX) Acquisition of Cellulose-based Live-Cell Encapsulation Technology Positions Company as a Leader in Development of Next Generation Cancer and Diabetes Treatments
Dec 11, 2013 Nuvilex's Contractor, Inno Biologics, Employs Clone-Pix(TM) Technology in Cloning Cells for Future Clinical Trials
Dec 9, 2013 Nuvilex Holds High Level Strategic Meetings to Solidify Company Objectives and Plans for Future Research and Development
Dec 6, 2013 Nuvilex's Subsidiary, Medical Marijuana Sciences, Inc., Appoints Dr. Mark L. Rabe as Chairman of Its Scientific Advisory Board
Dec 5, 2013 After Pancreatic Cancer, Eli Lilly and Nuvilex Could Battle Over Diabetes Treatment
Dec 4, 2013 Record Diabetes Cases Highlight Need for Nuvilex Treatment
Nov 29, 2013 Nuvilex Ahead of the Curve on Cannabidiol as FDA Issues Landmark Approval
Nov 25, 2013 Nuvilex Accelerates Development of Treatments for Cancer and Diabetes With New Corporate Management Structure
Nov 19, 2013 Nuvilex's Acquisition of Diabetes Rights Should Put the Company on Everyone's Radar
1
2
3
4
next >
